Early Detection Research Network

Semmes, John

Contact Information

Email: mailto:semmesoj@evms.edu
Fax: 757 446-5766
EDRN Principal Investigator
1333
None given

To update contact information, please visit the Data Management and Coordinating Center.

Open Protocols

Protocol Name Biomarkers Datasets
Body Fluids as a Source of Diagnostic Biomarkers 0 0
Body Fluids as a Source of Diagnostic Biomarkers: Breast 0 0
Collaborative study on SELDI biomarker discovery and serum protein profiling of lung cancers 0 0
Detecting breast cancer protein signatures in body fluid 0 0
Detection of Serum Markers of Breast Cancer by SELDI 0 0
EDRN Pre-Validation of Metabolic Biomarkers of Prostate Cancer: Follow up EDRN Challenge 0 0
EDRN Pre-Validation of Multiplex Biomarker in Urine 2 0
Establishment of a serum standard for use in high-throughput proteomic 0 0
HNPCC colon cancer-associated SELDI mass spectrometry protein profiles in serum 0 0
SELDI and LC-MS/MS discovery and profiling study of hepatocarcinomas 0 0
SELDI Profiling of serum and urine from patients with urologic disease in support of bladder cancer studies 0 0
Upgrading Reference Set 0 0

Closed Protocols

Protocol Name Biomarkers Datasets
Body Fluids as a Source of Diagnostic Biomarkers: Prostate 0 0
Early Detection of Cancer by Affinity Mass Spectrometry-Set Aside funds 0 0
EDRN-WHI Pre-Clinical Colon Ca Specimens 0 9
Protein profiling for detection of high risk breast cancer 0 0
Proteomic Profiling of Serum and Other Body Fluids for the Early Detection of Colon Cancers 0 0
SELDI Phase I: Assay Validation-Prostate 0 1
SELDI Validation Study Phase II 0 3

Publications

Publication Name PubMed ID Journal
A novel approach for clustering proteomics data using Bayesian fast Fourier transform. 15769836 Bioinformatics
A novel approach toward development of a rapid blood test for breast cancer. 14499014 Clin. Breast Cancer
Application of mass spectrometry to the discovery of biomarkers for detection of prostate cancer. 16552720 J. Cell. Biochem.
Clinical proteomics: A need to define the field and to begin to set adequate standards. 21136664 Proteomics Clin Appl
Data reduction using a discrete wavelet transform in discriminant analysis of very high dimensionality data. 12762451 Biometrics
Deconvolution filters to enhance resolution of dense time-of-flight survey spectra in the time-lag optimization range. 16636999 Rapid Commun. Mass Spectrom.
Defining the role of mass spectrometry in cancer diagnostics. 15466969 Cancer Epidemiol. Biomarkers Prev.
Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and posttreatment head and neck cancer samples. 18043497 Laryngoscope
Enhancement of sensitivity and resolution of surface-enhanced laser desorption/ionization time-of-flight mass spectrometric records for serum peptides using time-series analysis techniques. 15550476 Clin. Chem.
Expression of genes and proteins specific for prostate cancer. 15535438 J. Urol.
Feature extraction in the analysis of proteomic mass spectra. 16502467 Proteomics
Functional clustering algorithm for high-dimensional proteomics data. 16046812 J. Biomed. Biotechnol.
Identification of patients with head and neck cancer using serum protein profiles. 14732777 Arch. Otolaryngol. Head Neck Surg.
Measurement reproducibility in the early stages of biomarker development. 15665389 Dis. Markers
Mining the low molecular weight proteome of blood. 21136732 Proteomics Clin Appl
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. 18606634 Clin. Chem.
Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. 12171882 Clin. Cancer Res.
Optimization of MALDI-TOF MS detection for enhanced sensitivity of affinity-captured proteins spanning a 100 kDa mass range. 17918874 J. Proteome Res.
Overexpression of alpha-defensin is associated with bladder cancer invasiveness. 16520271 Urol. Oncol.
Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. 15112261 Cancer
Protein profiling in urine for the diagnosis of bladder cancer. 15277356 Clin. Chem.
Resampling and deconvolution of linear time-of-flight records for enhanced protein profiling. 16637003 Rapid Commun. Mass Spectrom.
SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers. 15258337 Dis. Markers
Selective capture of prostatic basal cells and secretory epithelial cells for proteomic and genomic analysis. 15283892 Urol. Oncol.
Serum biomarkers to differentiate benign and malignant mammographic lesions. 17481542 J. Am. Coll. Surg.
Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. 15709174 Clin. Cancer Res.
Serum protein profiles to identify head and neck cancer. 15014013 Clin. Cancer Res.
Serum, salivary and tissue proteomics for discovery of biomarkers for head and neck cancers. 15723595 Expert Rev. Mol. Diagn.
Signal detection in high-resolution mass spectrometry data. 18173224 J. Proteome Res.
Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. 15383419 Ann. Surg. Oncol.
The "omics" haystack: defining sources of sample bias in expression profiling. 16120944 Clin. Chem.
The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology. 15283893 Urol. Oncol.

To update protocols, publications, biomarkers, or science data, please contact the Informatics Center.